EPISURF Aktie

 

Episurf Medical AB (publ) (Nasdaq: EPIS B) has entered into an agreement to acquire a portfolio consisting of 36 properties, primarily LSS housing facilities, with a total agreed property value of approximately SEK 697 million. The acquisition is carried out through Episurf acquiring all shares in Bolaget XX22 AB and its wholly-owned subsidiary Mofast Invest II AB and indirect subsidiaries from Mofast AB (Publ), thereby further strengthening the Company's real estate initiative with a diversified portfolio of social infrastructure properties with stable rental income. “The Mofast acquisition...

Episurf Medical's annual report for 2025 is available as of today at the company's website, www.episurf.com.   Episurf Medical has of environmental and cost reasons chosen not to print the annual report. A printed version of the annual report will be distributed to shareholders and others who made such request. The annual report can also be ordered from Episurf Medical on the following address: Episurf Medical AB, Karlavägen 60, 114 49 Stockholm, Sweden or by email: ir@episurf.com.  For further information, please contact:  Jens Andersson, CEO, Episurf Medical  Email: jens....

The shareholders in Episurf Medical AB (publ), 556767-0541 ("Episurf" or the "Company"), are hereby summoned to the Extraordinary General Meeting (the "Meeting") on 13 April 2026, at 15:00 (CEST) at the Company's office at Karlavägen 60, SE-114 49 Stockholm, Sweden. Entry and registration begin at 14:30 (CEST). The Board of Directors has, pursuant to Chapter 7, Section 4 a of the Swedish Companies Act (Sw. aktiebolagslagen (2005:551)) and the Company's Articles of Association, resolved that shareholders shall be able to exercise their voting rights by post prior to the Meeting. Accordingly,...

Episurf Medical (Nasdaq: EPIS B) has today decided to change the date of the Annual General Meeting 2026 as well as the publication dates for the interim report for January–March 2026 and the Annual Report for 2025. The publication of the Annual Report for 2025 is rescheduled from 6 March 2026 to 20 March 2026. The Annual General Meeting 2026 is rescheduled from 10 April 2026 to 25 May 2026. The interim report for the period January–March 2026 is rescheduled from 24 April 2026 to 25 May 2026. An updated financial calendar will be available on the company's website. For...

As a result of, in accordance with previously announced information, the exercise of 450,494,390 warrants of series TO14 B for subscription of the same number of new Class B shares, as well as the directed issue of 700,238,622 Class B shares, the number of shares and votes in Episurf Medical AB (publ) ("Episurf") has changed. Through the above-mentioned changes, the total number of shares in Episurf amounts to 2,810,494,390, of which 473,357 are Class A shares and 2,810,021,033 are Class B shares, and the total number of votes in Episurf amounts to 2,811,441,104. For further...

Episurf Medical (NASDAQ: EPIS B) has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a new patent. The patent, entitled “Metatarsal implant”, relates to the big toe implant that the company has developed. This is the first approval within this patent family. “This patent gives us protection in the US within the field of implants for the metatarsal bone of the toe. This relates to the Episealer® MTP implant for the big toe that the company has developed, a product that is currently undergoing a review process at the US FDA. We are delighted to...

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO AUSTRALIA, BELARUS, CANADA, HONG KONG, ISRAEL, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND, THE UNITED KINGDOM, THE UNITED STATES OR ANY OTHER JURISDICTION WHERE SUCH PUBLICATION, DISTRIBUTION OR DISCLOSURE WOULD BE IN VIOLATION OF APPLICABLE LAWS OR REQUIRE ADDITIONAL REGISTRATION OR ANY OTHER MEASURES. PLEASE REFER TO THE SECTION "IMPORTANT INFORMATION" AT THE END OF THIS PRESS RELEASE. The Board of Directors of Episurf Medical AB (publ) ("Episurf" or...

THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, THE UNITED KINGDOM, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, ISRAEL, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION WOULD REQUIRE ADDITIONAL PROSPECTUS, REGISTRATION OR OTHER MEASURES IN ADDITION TO THOSE REQUIRED BY SWEDISH LAW, IS PROHIBITED, OR OTHERWISE IS UNLAWFUL OR CANNOT BE MADE WITHOUT THE APPLICATION OF AN EXEMPTION FROM SUCH ACTION. REFER TO THE SECTION “IMPORTANT...

In accordance with the decision by the Annual General Meeting, Episurf Medical's Nomination Committee shall consist of four members. The members are selected by the three largest shareholders in the company that wish to participate in the Committee. In addition, the Chairman of the Board is to be appointed to the Nomination Committee. The members of the Nomination Committee shall agree on a chairman/woman of the Committee. In accordance with the above principles, the Nomination Committee consists of the following four members: · Ulf Grunander, Chairman of the Board Episurf Medical...

Episurf Medical (Nasdaq: EPIS B) announces leadership changes effective from 11 February 2026. Jens Andersson, elected as a Board member of Episurf at the Extraordinary General Meeting on 10 February, will assume the role of Chief Executive Officer (CEO), succeeding Katarina Flodström. Katarina Flodström has been appointed Deputy CEO and Head of the company's medical technology operations. At the same time, Sanja Batljan has been appointed Chief Financial Officer (CFO), succeeding Pål Ryfors, who will thereby leave Episurf. “I am pleased that Jens Andersson and Sanja Batljan, both...

Episurf Medical AB (publ) today 10 February 2026 held an extraordinary general meeting in Stockholm. Approval of the acquisition etc. The extraordinary general meeting resolved, in accordance with the board of directors' proposal, to approve the acquisition of the company Frusipe Intressenter Target 1 AB, which holds a portfolio of assets consisting of properties and bonds for a preliminary consideration of maximum SEK 1,147 million (the “Acquisition”). The Acquisition is described in further detail in the press release published by the company on 30 December 2025. The...

THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, THE UNITED KINGDOM, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, ISRAEL, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION WOULD REQUIRE ADDITIONAL PROSPECTUS, REGISTRATION OR OTHER MEASURES IN ADDITION TO THOSE REQUIRED BY SWEDISH LAW, IS PROHIBITED, OR OTHERWISE IS UNLAWFUL OR CANNOT BE MADE WITHOUT THE APPLICATION OF AN EXEMPTION FROM SUCH ACTION. REFER TO THE SECTION “IMPORTANT...

Episurf Medical AB (publ) (NASDAQ: EPIS B) (“Episurf" or the “Company”) has today, 26 January 2026, entered into an agreement regarding the acquisition of a property portfolio consisting of residential properties in Bollnäs, a shopping center in Västervik and two properties in Trelleborg with a total underlying agreed property value of MSEK 897 (the "Property Portfolio"). The purpose of the Acquisition is to further strengthen the Company's property vertical and expand the Company's exposure to a diversified portfolio. The preliminary purchase price for the Acquisition amounts to...

The shareholders in Episurf Medical AB (publ), 556767-0541 (“Episurf” or the “Company”), are hereby summoned to the Extraordinary General Meeting (the “Meeting”) on 10 February 2026, at 08:00 (CET) at the Company's office at Karlavägen 60, SE-114 49 Stockholm, Sweden. Entry and registration begin at 07:45 (CET). The Board of Directors has, pursuant to Chapter 7, Section 4 a of the Swedish Companies Act (Sw. aktiebolagslagen (2005:551)) and the Company's Articles of Association, resolved that shareholders shall be able to exercise their voting rights by post prior to the Meeting. Accordingly,...

Episurf Medical AB (publ) (NASDAQ: EPIS B) ("Episurf" or the "Company") announced on 30 December 2025, that the Company has entered into an agreement to acquire real estate assets from Goldcup 38657 AB (under name change to Frusipe Intressenter Holding AB) (the "Seller"). Episurf has today acquired all shares in Goldcup 38658 AB (under name change to Frusipe Intressenter Target 1 AB) (the "Target Company") which, currently through subsidiaries, holds and manages property portfolios consisting of a total of 4 Swedish properties, with a total agreed underlying property value of approximately...

The Board of Directors of Episurf Medical AB (publ) (NASDAQ: EPIS B) ("Episurf" or the "Company") has today, 30 December 2025, entered into an agreement with Goldcup 38657 AB (under name change to Frusipe Intressenter Holding AB) (the "Seller"), regarding the acquisition of all shares in Goldcup 38658 AB (under name change to Frusipe Intressenter Target 1 AB) (the "Target Company"), a wholly owned subsidiary of the Seller (the "Acquisition"). The Target Company is a newly formed Swedish limited liability company which, through subsidiaries, holds and manages property portfolios consisting...

Episurf Medical (NASDAQ: EPIS B) today announces an update on the process for US market clearance for the company's Episealer® MTP big toe implant. Episurf Medical has addressed the feedback earlier received from the US FDA on the company's 510(k) submission for market clearance, and has now performed a new submission. The Episealer® MTP technology includes patient-specific implants and instrumentation, developed to address osteoarthritis in the MTP joint of the big toe. “This submission implies that the company has finalised the activities initiated to address FDA's previous feedback....

Episurf Medical (Nasdaq: EPIS B) today announces that the company's implants Episealer® Knee and Episealer® Talus have successfully gone through the medical devices product registration process of Singapore's Health Sciences Authority (HSA) and are approved for sale. Episealer® Knee and Episealer® Talus are Episurf Medical's implants for the treatment of focal joint lesions in the knee and ankle, respectively. “While the company has a focus on sales in the US and Europe, we still welcome approvals for sale in additional distribution markets, for increased dissemination of the company'...

Episurf Medical (Nasdaq: EPIS B) today announces that Laura Shunk, at her own request, resigns from her position as a member of the Board of Directors of Episurf Medical AB due to personal reasons. Laura Shunk has served as a member of Episurf Medical's Board since 2017. "On behalf of the Board, I would like to thank Laura for her valuable contributions. I look forward to convene the nomination committee to put together a proposal for a strengthened board for Episurf" says Ulf Grunander, Chairman of the Board, Episurf Medical. For more information, please contact: Katarina...

· Strong US growth in gross-order intake and customer base · Significantly improved financial results · Continued focus on regulatory pathway for MTP-implant “This is my first CEO statement as CEO of Episurf Medical, although I have been with the company since its inception. I will work hard to ensure that we achieve our goals, and I fully support our strategy to drive sales in our most important markets, achieve FDA clearance for our toe implant Episealer® MTP, and to deliver on the cost-saving program we launched earlier this year. If we successfully execute these initiatives, we...